Nomura Asset Management Co. Ltd. Trims Stock Holdings in argenx SE (NASDAQ:ARGX)

Nomura Asset Management Co. Ltd. decreased its stake in shares of argenx SE (NASDAQ:ARGX - Free Report) by 32.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,653 shares of the company's stock after selling 2,254 shares during the quarter. Nomura Asset Management Co. Ltd.'s holdings in argenx were worth $2,862,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of ARGX. Charles Schwab Investment Management Inc. increased its position in argenx by 28.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 3,459 shares of the company's stock valued at $1,875,000 after buying an additional 768 shares in the last quarter. Bank of Montreal Can grew its stake in argenx by 9.4% in the third quarter. Bank of Montreal Can now owns 8,307 shares of the company's stock valued at $4,453,000 after acquiring an additional 714 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of argenx by 4,344.2% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 40,842 shares of the company's stock valued at $22,140,000 after acquiring an additional 39,923 shares in the last quarter. Captrust Financial Advisors acquired a new position in shares of argenx during the third quarter worth approximately $243,000. Finally, Hilltop Holdings Inc. bought a new position in shares of argenx in the 3rd quarter worth $281,000. Institutional investors own 60.32% of the company's stock.

argenx Trading Down 0.9 %

Shares of ARGX stock traded down $5.11 during trading hours on Monday, hitting $550.00. 661,910 shares of the company were exchanged, compared to its average volume of 298,932. argenx SE has a 52-week low of $352.77 and a 52-week high of $678.21. The firm has a fifty day simple moving average of $619.46 and a 200 day simple moving average of $603.79. The stock has a market capitalization of $33.42 billion, a price-to-earnings ratio of -625.00 and a beta of 0.60.

Remove Ads

argenx (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.60. The firm had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. Sell-side analysts anticipate that argenx SE will post 3.13 EPS for the current year.

Analyst Upgrades and Downgrades

ARGX has been the subject of a number of recent research reports. HC Wainwright boosted their price target on shares of argenx from $717.00 to $720.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Robert W. Baird boosted their target price on shares of argenx from $650.00 to $680.00 and gave the stock a "neutral" rating in a research report on Tuesday, March 4th. Sanford C. Bernstein upgraded shares of argenx from a "market perform" rating to an "outperform" rating in a report on Monday, March 17th. JMP Securities lifted their price target on argenx from $606.00 to $696.00 and gave the company a "market outperform" rating in a research note on Tuesday, January 14th. Finally, Oppenheimer increased their price objective on argenx from $675.00 to $704.00 and gave the stock an "outperform" rating in a research note on Friday, February 28th. Three investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $687.00.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.